---
title: Detect early cognitive decline Parkinsons
nct_id: NCT05025254
status: RECRUITING
sponsor: McGill University
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05025254"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05025254"
last_fetched: "2026-05-10T14:05:57.816Z"
source: "Parkinson's Pathways (curated)"
---
# Detect early cognitive decline Parkinsons

**Goal (in five words):** Detect early cognitive decline Parkinsons

**Official Title:** Deep Cognitive Endophenotyping of Parkinson's Disease: A Platform Development and Pilot Study

**Trial ID:** [NCT05025254](https://clinicaltrials.gov/study/NCT05025254)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** McGill University
- **Target Enrollment:** 1000 participants
- **Start Date:** 2021-08
- **Completion Date:** 2022-09
- **Conditions:** Parkinson Disease
- **Interventions:** Neurocognitive testing
- **Intervention Types:** OTHER

## Summary For Families

The goal is to create a detailed cognitive fingerprint to better identify and track the thinking and memory changes that happen in Parkinson's, and to develop sensitive tools for future research or care. The approach is observational neurocognitive testing, using paper and computer tasks that measure memory, attention, language, and problem solving to detect subtle changes earlier than routine exams; it does not test a drug and does not change your Parkinson's medications. The study is looking for people aged 45 to 90 with Parkinson's diagnosed by a neurologist, plus healthy adults with no neurological illness as controls. People with psychotic spectrum disorders, uncontrolled depression, advanced dementia needing daily help, major stroke, major head injury, or epilepsy treated with anti-seizure medications are not eligible.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 90 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* diagnosis of Parkinson's disease by neurologist or healthy individual with no diagnosis of any neurological illness

Exclusion Criteria:

* Psychotic spectrum disorders, active uncontrolled depression, advanced dementia (i.e. needing assistance with daily activities such as dressing or bathing), major stroke, major head injury, epilepsy requiring anti-seizure medications
```

## Locations (1)

- McGill University Health Centre, Montreal, Quebec, Canada _(45.5088, -73.5878)_
  - Madeleine Sharp — (CONTACT) — madeleine.sharp@mcgill.ca

## Central Contacts

- Madeleine Sharp, MD — (CONTACT) — 514-398-5174 — madeleine.sharp@mcgill.ca

---

*Canonical: https://parkinsonspathways.com/trial/NCT05025254*  
*HTML version: https://parkinsonspathways.com/trial/NCT05025254*  
*Source data: https://clinicaltrials.gov/study/NCT05025254*